GSK plc (LON:GSK) Given Average Rating of “Moderate Buy” by Analysts

Shares of GSK plc (LON:GSK) have received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is GBX 1,805.83 ($23.34).

GSK has been the topic of a number of analyst reports. Berenberg Bank cut their target price on GSK from GBX 1,820 ($23.53) to GBX 1,600 ($20.68) and set a “buy” rating on the stock in a research note on Friday, November 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Tuesday, January 7th.

GSK Stock Performance

GSK opened at GBX 1,534 ($19.83) on Wednesday. The company has a market capitalization of £62.25 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company’s 50 day simple moving average is GBX 1,407.87. GSK has a one year low of GBX 1,282.50 ($16.58) and a one year high of GBX 1,823.50 ($23.57). The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last released its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other GSK news, insider Emma Walmsley sold 38,459 shares of the company’s stock in a transaction on Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($18.33), for a total transaction of £545,348.62 ($704,949.10). Also, insider Jonathan Symonds bought 1,500 shares of the stock in a transaction on Friday, December 20th. The shares were bought at an average price of GBX 1,315 ($17.00) per share, with a total value of £19,725 ($25,497.67). 1.61% of the stock is owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.